Hisse Senetlerindeki Sıralama
#4588
uniQure N.V. develops treatments for patients suffering from rare and other... uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Ticaret UniQure N.V. (QURE)
B piyasa değeri ile QURE fiyatı
Piyasa Değeri UniQure N.V.(QURE)
Piyasa Değeri: $3.51B
August 2026 itibarıyla UniQure N.V. şirketinin piyasa değeri $3.51B. Bu, verilerimize göre UniQure N.V. şirketini dünyanın en değerli 4588th. şirketi yapar. Piyasa değeri, halka açık bir şirketin tedavüldeki hisse senetlerinin toplam piyasa değeri olup, bir şirketin değerini ölçmek için yaygın olarak kullanılır.
UniQure N.V. piyasa değeri geçmişi (2014 - 2026)
En Popüler 5 stocks ile karşılaştırıldığında QURE
| QURE’in Fiyatı |
|
B Varlığı |
B’nin Piyasa Değeri |
Sonuçlar |
|
|
|
|
$5.088T
|
+144,669.88%
|
|
|
|
|
$4.629T
|
+131,615.89%
|
|
|
|
|
$4.118T
|
+117,061.78%
|
|
|
|
|
$3.687T
|
+104,801.56%
|
|
|
|
|
$2.800T
|
+79,560.94%
|
